Home Tags SMDC

Tag: SMDC

Fishing in the Dark: How to Find New, Targeted Drugs

Searching for new drugs is like fishing in the dark: the prospect of catching something is very uncertain, and it requires patience, skill and...

What to Expect at the 17th World Conference on Lung Cancer

An estimated 225,000 Americans are expected to be diagnosed with lung cancer this year. Recurrent Small Cell Lung Cancer or accounts for 10%...

Goodwin Biotechnology: Mastering Novel Conjugation Approaches

Often described as target-seeking molecular missiles with a lethal warhead, antibody-drug conjugates have, over the last 15 years, shown to have staying power. With...

TARGET trial Shows Improved OS in Patients with FR+ Recurrent NSCLC...

The final overall survival (OS) analysis from the Phase IIb TARGET trial evaluating Endocyte's small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in...
ESMO 2014 Congress - Madrid, Spain

Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated with...

Interim results from the phase IIb TARGET Trial, presented as Late-Breaking News at the annual meeting of the European Society for Medical Oncology (ESMO), being held September 26 - 30, 2014 in Madrid, Spain, shows improved survival in adenocarcinoma non-small cell lung cancer patients treated the small molecule drug conjugate (SMDC) vintafolide, being developed byEndocyte, in combination with docetaxel (Taxotere®; Sanofi).[1]